NextPlat NXPL
NASDAQ NXPL
$9.05 -0.05 (-0.62%)
As of: Oct 20, 2026 · 3:59 PM EDT

NextPlat (NXPL) Research & Development (2011 - 2013)

Updated

NextPlat (NXPL) recorded Research & Development of $115,832 in FY2012, down 25.9% from $156,363 in FY2011.

Analysis

NextPlat (NXPL) Research & Development (2011 - 2013) Analysis & Trends

  • Per Business Quant data, NXPL's Research & Development was $156,363 in FY2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn 3.82 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn 3.65 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn 2.34 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn 9.74 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn 2.85 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn 4.05 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn 1.87 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn 1.76 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn 2.81 Bn
10 NextPlat 23.29 Mn -27.29 Mn 4.69 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2013 5,000.00
Sep 30, 2012 43,165.00
Jun 30, 2012 29,587.00
Mar 31, 2012 10,949.00
Dec 31, 2011 31,451.00
Sep 30, 2011 63,292.00
Jun 30, 2011 61,620.00
API Access

NextPlat Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=NXPL&period=max&api_key=YOUR_API_KEY